Welcome to our dedicated page for Stereotaxis Ord SEC filings (Ticker: STXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stereotaxis, Inc. (NYSE: STXS) SEC filings page provides direct access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on financial performance, risk factors, capital structure, and material events related to Stereotaxis’ surgical robotics and medical device business for minimally invasive endovascular intervention.
Among the key filings, investors can review current reports on Form 8-K, which Stereotaxis uses to announce material events such as quarterly earnings press releases and financing arrangements. For example, Form 8-K filings reference earnings releases for specific quarters and describe a Sales Agreement with Roth Capital Partners, LLC that allows at-the-market offerings of common stock under an effective shelf registration statement on Form S-3. These filings outline intended uses of proceeds, including working capital, research and development, and commercialization of the company’s innovation pipeline.
In addition to 8-Ks, the company’s broader SEC record (including Forms 10-K and 10-Q, when available) contains information on revenue from systems and from disposables, service, and accessories, as well as operating expenses, liquidity, and other financial metrics. Proxy statements and related documents can provide further detail on governance and equity structure, while Form 4 and other insider transaction reports, when filed, show share transactions by directors and officers.
On this page, Stock Titan pairs real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy filings. Instead of reading every line of a multi-hundred-page annual report or parsing technical language in a current report, users can use AI-generated overviews to understand the context of Stereotaxis’ filings, then drill down into the original documents for deeper analysis. This helps investors, analysts, and researchers quickly interpret how regulatory disclosures relate to Stereotaxis’ surgical robotics, catheter portfolio, and digital cath lab initiatives.
Stereotaxis, Inc. (STXS) insider Paul J. Isaac reported open-market purchases of the company’s common stock. On 11/14/2025, an indirect account bought 20,000 shares at $2.24 per share, bringing indirect beneficial ownership to 2,786,557 shares held through Arbiter Partners Capital Management LLC and related managed accounts. On 11/17/2025, a direct account purchased 10,000 shares at $2.18 per share, resulting in 97,299 shares held directly. The filing explains that Arbiter is a registered investment adviser, that Isaac’s reported holdings include shares owned by an affiliated fund and managed accounts, and that he disclaims beneficial ownership except to the extent of his pecuniary interest.
The remarks note that Ross B. Levin, Arbiter’s Director of Research, serves on Stereotaxis’s board of directors and that this Form 4 is filed as a matter of caution without conceding that Isaac, Arbiter or the fund are statutory insiders.
Stereotaxis (STXS) reported Q3 2025 results. Revenue was $7.5 million, down from $9.2 million a year ago, as systems sales softened while disposables, service and accessories grew. Systems revenue was $1.9 million versus $4.4 million, and disposables, service and accessories reached $5.6 million versus $4.8 million.
Gross margin was $4.1 million, roughly flat year over year, while operating loss was $6.6 million versus $6.3 million. Net loss was $6.5 million compared with $6.2 million, and basic/diluted EPS was ($0.07) versus ($0.08). For the first nine months, revenue rose to $23.7 million from $20.6 million, reflecting stronger recurring revenue. Cash and cash equivalents were $10.5 million at September 30, 2025. Deferred revenue totaled $8.1 million, supporting future service and delivery obligations.
The company continued integrating Access Point Technologies (APT), which contributed $4.1 million in revenue for the nine months. Stereotaxis established a $50.0 million at‑the‑market program on August 29, 2025, with no shares issued under it through quarter-end. Shares outstanding were 93,324,763 as of October 31, 2025.
Stereotaxis, Inc. furnished its third‑quarter 2025 financial results via a press release attached as Exhibit 99.1 to an 8‑K. The company noted that statements in the release may include forward‑looking statements subject to risks and uncertainties. Under General Instruction B.2, the information in Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and will be incorporated by reference only if expressly cited in future filings.
Stereotaxis, Inc. may offer and sell up to $50 million of its common stock through an at-the-market program under a Sales Agreement with Roth Capital Partners. Shares can be sold from time to time on the NYSE American or in other permitted transactions, with Roth acting as sales agent or, on occasion, as principal.
Roth will receive up to 3.0% of the gross proceeds from any shares sold, plus expense reimbursements, and will be deemed an underwriter for regulatory purposes. Assuming an illustrative sale of 17,421,602 shares at $2.87 per share, total common stock outstanding would rise to 108,493,081 shares, which would dilute existing holders.
Stereotaxis intends to use any net proceeds for working capital, research and development, and other general corporate purposes, including accelerating commercialization of its innovation pipeline. The company notes that its common stock does not currently pay cash dividends, so potential returns would primarily depend on share price appreciation.
Stereotaxis, Inc. entered into a Sales Agreement with Roth Capital Partners that allows the company to sell shares of its common stock with an aggregate sales price of up to $50,000,000 through at-the-market offerings or privately negotiated transactions. These potential sales are covered by an existing Form S-3 shelf registration that permits up to $100,000,000 of securities, with a new prospectus supplement dated August 29, 2025.
Roth Capital will act as sales agent and/or principal and earn a placement fee of up to 3.0% of the gross sales price of any shares sold, plus specified expense reimbursements. Stereotaxis plans to use any net proceeds for working capital, research and development, and other general corporate purposes, including accelerated commercialization of its innovation pipeline. The company is not obligated to sell any shares, and the program can be suspended or terminated by either party under the agreement’s terms.
Stereotaxis, Inc. reported stronger top-line results for the quarter ended June 30, 2025, with total revenue of $8.8 million, up from $4.5 million a year earlier, and $16.3 million for the six months versus $11.4 million in 2024. Growth was driven by higher systems sales ($3.0 million in Q2 2025 versus $0.24 million) and increased disposables, service and accessories revenue. Gross margin improved to $4.6 million in the quarter from $3.3 million a year ago, and operating loss narrowed to $4.0 million from $6.0 million in the prior-year quarter.
Despite improved operating performance, the company remains unprofitable with a six-month net loss of $9.6 million and a cumulative deficit of approximately $571.4 million. Cash and cash equivalents were $6.97 million at June 30, 2025, and operating cash used was $5.5 million for the six months. The company completed an earlier acquisition of Access Point Technologies (APT), recognized related intangible assets and goodwill, recorded a $0.5 million contingent consideration revaluation charge, and disclosed a July 2025 registered offering with initial gross proceeds of $8.5 million and $4.0 million expected at a later closing.